India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Phase 3 Clinical Trial of COVAXIN, developed by ICMR & Bharat Biotech, shows 81% efficacy
The results, evaluated by an independent data safety and monitoring board, show that the vaccine is well-tolerated and efficacious against SARS-CoV-2 across a wide range of age groups and variants in the country
New Delhi, 3 March 2021: Phase 3 results of the COVAXIN, developed by Indian Council of Medical Research (ICMR)in partnership with Bharat Biotech International Limited (BBIL),has shown an interim vaccine efficacy of 81% in preventing Covid-19. The Phase 3 trial, jointly initiated by ICMR and BBIL in mid-November 2020,wasconducted in a total of 25,800 individuals across 21 sites. The interim efficacy trend of 81%, analyzed as per the protocol approved by the DCGI, puts it at par with other global front-runner vaccines. “The bench-to-bedside journey of completely indigenous COVID-19 vaccine in less than 8months’ time showcases the immense strength of Atmanirbhar Bharat[self-reliant India] to fight the odds and stand tall in the global public health community. It is also a testament to India’s emergence as a global vaccine superpower” said Dr. Balram Bhargava, Director General, ICMR. The COVAXIN is the first COVID-19 vaccine that has been developed completely in India…